Erratum: Next-generation sequencing-based genome diagnostics across clinical genetics centers: Implementation choices and their effects (European Journal of Human Genetics (2015) 23 (1142-1150) DOI:10.1038/ejhg.2014.279);Next-generation sequencing-based genome diagnostics across clinical genetics centers: Implementation choices and their effects

European Journal of Human Genetics

Volumn 23, Issue 9, 2015, Pages 1142-1150

  Vrijenhoek, Terry ^a   Kraaijeveld, Ken ^b   Elferink, Martin ^a   De Ligt, Joep ^c   Kranendonk, Elcke ^d   Santen, Gijs ^b   Nijman, Isaac J ^a   Butler, Derek ^e   Claes, Godelieve ^f   Costessi, Adalberto ^e   Dorlijn, Wim ^g   Van Eyndhoven, Winfried ^g   Halley, Dicky J J ^h   Van Den Hout, Mirjam C G N ^h   Van Hove, Steven ⁱ   Johansson, Lennart F ^j   Jongbloed, Jan D H ^j   Kamps, Rick ^f   Kockx, Christel E M ^h   De Koning, Bart ^f   Kriek, Marjolein ^b   Lekanne Dit Deprez, Ronald ^d   Lunstroo, Hans ^k   Mannens, Marcel ^d   Mook, Olaf R ^d   Nelen, Marcel ^c   Ploem, Corrette ^d   Rijnen, Marco ^l   Saris, Jasper J ^h   Sinke, Richard ^j   Sistermans, Erik ^m   Van Slegtenhorst, Marjon ^h   Sleutels, Frank ^h   Van Der Stoep, Nienke ^b   Van Tienhoven, Marianne ^h   Vermaat, Martijn ^b   Vogel, Maartje ^a   Waisfisz, Quinten ^m   Marjan Weiss, Janneke ^m   Van Den Wijngaard, Arthur ^f   Van Workum, Wilbert ⁿ   Ijntema, Helger ^c   Van Der Zwaag, Bert ^a   Van Ijcken, Wilfred F J ^h   Den Dunnen, Johan ^b   Veltman, Joris A ^c   Hennekam, Raoul ^d   Cuppen, Edwin ^a   more..

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e BaseClear BV   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g Agilent Technologies Netherlands BV   (Netherlands)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ Illumina Inc   (Netherlands)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^k Roche NimbleGen Inc   (United States)

^l Life Technologies Europe BV   (Netherlands)

^m VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ ServiceXS   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA; CALCIUM BINDING PROTEIN; CARDIAC MYOSIN; CARRIER PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MYH7 PROTEIN, HUMAN; MYOSIN HEAVY CHAIN; MYOSIN-BINDING PROTEIN C; PHOSPHOLAMBAN; TNNI3K PROTEIN, HUMAN;

ADULT; ARTICLE; BIOINFORMATICS; CARDIOMYOPATHY; CGC1 GENE; CGC8 GENE; CLINICAL ARTICLE; CLINICAL GENETICS; CLINICAL PRACTICE; COMPARATIVE STUDY; CONTROLLED STUDY; EXOME; FABRY DISEASE; GENE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LABORATORY PERSONNEL; MEDICAL RESEARCH; MEDICAL SPECIALIST; MOLECULAR DIAGNOSIS; MOLECULAR DIAGNOSTICS; MYBPC3 GENE; NETHERLANDS; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; CARDIOMYOPATHIES; CLINICAL TRIAL; DEVICES; GENE EXPRESSION; GENETICS; GOOD LABORATORY PRACTICE; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; INFORMED CONSENT; LEGISLATION AND JURISPRUDENCE; MULTICENTER STUDY; MUTATION; PROCEDURES; STANDARDS; STATISTICS AND NUMERICAL DATA;

CALCIUM-BINDING PROTEINS; CARDIAC MYOSINS; CARDIOMYOPATHIES; CARRIER PROTEINS; EXOME; GENE EXPRESSION; GENETIC TESTING; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFORMED CONSENT; LABORATORY PROFICIENCY TESTING; MAP KINASE KINASE KINASES; MUTATION; MYOSIN HEAVY CHAINS; NETHERLANDS;

EID: 84939272234     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2015.44     Document Type: Erratum

References (67)

1. de Vries BBA, Pfundt R, Leisink M et al: Diagnostic genome profiling in mental retardation. Am J Hum Genet 2005; 77: 606-616.
2. Mardis ER: The impact of next-generation sequencing technology on genetics. Trends Genet 2008; 24: 133-141.
3. Biesecker LG: Hypothesis-generating research and predictive medicine. Genome Res 2013; 23: 1051-1053.
4. Gilissen C, Hoischen A, Brunner HG, Veltman JA: Disease gene identification strategies for exome sequencing. Eur J Human Genet 2012; 20: 490-497.
5. Boomsma DI, Wijmenga C, Slagboom EP et al: The genome of the Netherlands: design, and project goals. Eur J Hum Genet 2014; 22: 221-227.
6. The Genome of the Netherlands C: whole-genome sequence variation, population structure and demographic history of the Dutch population. Nat Genet 2014; 46: 818-825.
7. Abecasis GR, Auton A, Brooks LD et al. 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature 2012; 491:56-65.
8. Levy S, Sutton G, Ng PC et al: The diploid genome sequence of an individual human. PLoS Biol 2007; 5: e254.
9. Lupski JR, Reid JG, Gonzaga-Jauregui C et al: Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med 2010; 362: 1181-1191.
10. McKernan KJ, Peckham HE, Costa GL et al: Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding. Genome Res 2009; 19: 1527-1541.
11. Wang J, Wang W, Li R et al: The diploid genome sequence of an Asian individual. Nature 2008; 456: 60-65.
12. Wheeler DA, Srinivasan M, Egholm M et al: The complete genome of an individual by massively parallel DNA sequencing. Nature 2008; 452: 872-876.
13. Ng SB, Buckingham KJ, Lee C et al: Exome sequencing identifies the cause of a mendelian disorder. Nat Genet 2010; 42: 30-35.
14. Hoischen A, van Bon BW, Gilissen C et al: De novo mutations of SETBP1 cause Schinzel Giedion syndrome. Nat Genet 2010; 42: 483-485.
15. Ng SB, Bigham AW, Buckingham KJ et al: Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nature Genet 2010; 42: 790-793.
16. Worthey EA, Mayer AN, Syverson GD et al: Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med 2011; 13: 255-262.
17. Gonzaga-Jauregui C, Lupski JR, Gibbs RA: Human genome sequencing in health and disease. Ann Rev Med 2012; 63: 35-61.
18. Veltman JA, Brunner HG: De novo mutations in human genetic disease. Nat Rev Genet 2012; 13: 565-575.
19. Vissers LE, de Ligt J, Gilissen C et al: A de novo paradigm for mental retardation. Nat Genet 2010; 42: 1109-1112.
20. O'Roak BJ, Vives L, Fu W et al: Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 2012; 338: 1619-1622.
21. Xu B, Roos JL, Dexheimer P et al: Exome sequencing supports a de novo mutational paradigm for schizophrenia. Nat Genet 2011; 43: 864-868.
22. Bras J, Guerreiro R, Hardy J: Use of next-generation sequencing and other whole-genome strategies to dissect neurological disease. Nat Rev Neurosci 2012; 13: 453-464.
23. Faye LL, Machiela MJ, Kraft P, Bull SB, Sun L: Re-ranking sequencing variants in the post-GWAS era for accurate causal variant identification. PLoS Genet 2013; 9: e1003609.
24. Flannick J, Thorleifsson G, Beer NL et al: Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nat Genet 2014; 46: 357-363.
25. Katsanis SH, Katsanis N: Molecular genetic testing and the future of clinical genomics. Nat Rev Genet 2013; 14: 415-426.
26. Mefford HC: Diagnostic exome sequencing are we there yet? N Engl J Med 2012; 367: 1951-1953.
27. Nelen M, Veltman JA: Genome and exome sequencing in the clinic: unbiased genomic approaches with a high diagnostic yield. Pharmacogenomics 2012; 13: 511-514.
28. Samani NJ, Tomaszewski M, Schunkert H: The personal genome-The future of personalised medicine? Lancet 2010; 375: 1497-1498.
29. Mardis ER: A decade's perspective on DNA sequencing technology. Nature 2011; 470: 198-203.
30. de Ligt J, Willemsen MH, van Bon BWM et al: Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med 2012; 367: 1921-1929.
31. Fokstuen S, Lyle R, Munoz A et al: A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy. Hum Mutat 2008; 29: 879-885.
32. Eid J, Fehr A, Gray J et al: Real-time DNA sequencing from single polymerase molecules. Science 2009; 323: 133-138.
33. Maitra RD, Kim J, Dunbar WB: Recent advances in nanopore sequencing. Electrophoresis 2012; 33: 3418-3428.
34. Clarke J, Wu HC, Jayasinghe L, Patel A, Reid S, Bayley H: Continuous base identification for single-molecule nanopore DNA sequencing. Nat Nanotechnol 2009; 4: 265-270.
35. Neveling K, Collin RWJ, Gilissen C et al: Next-generation genetic testing for retinitis pigmentosa. Hum Mutat 2012; 33: 963-972.
36. Need AC, Shashi V, Hitomi Y et al: Clinical application of exome sequencing in undiagnosed genetic conditions. J Med Genet 2012; 49: 353-361.
37. Klee EW, Hoppman-Chaney NL, Ferber MJ: Expanding DNA diagnostic panel testing: is more better? Expert Rev Mol Diagn 2011; 11: 703-709.
38. Shanks ME, Downes SM, Copley RR et al: Next-generation sequencing (NGS) as a diagnostic tool for retinal degeneration reveals a much higher detection rate in early-onset disease. Eur J Hum Genet 2013; 21: 274-280.
39. Weiss MM, Van der Zwaag B, Jongbloed JDH et al: Best practice guidelines for the use of next-generation sequencing applications in genome diagnostics: A National Collaborative Study of Dutch Genome Diagnostic Laboratories. Hum Mutat 2013; 34: 1313-1321.
40. Winkens RA, Ament AJ, Pop P, Reniers PH, Grol RP, Knottnerus JA: Routine individual feedback on requests for diagnostic tests: an economic evaluation. Med Decis Making 1996; 16: 309-314.
41. Ormond KE, Wheeler MT, Hudgins L et al: Challenges in the clinical application of whole-genome sequencing. Lancet 2010; 375: 1749-1751.
42. Kathiresan S, Srivastava D: Genetics of human cardiovascular disease. Cell 2012; 148: 1242-1257.
43. Kelly M, Semsarian C: Multiple mutations in genetic cardiovascular disease: a marker of disease severity?. Circ Cardiovasc Genet 2009;2:182-190.
44. Fokkema IFAC, Taschner PEM, Schaafsma GCP, Celli J, Laros JFJ, den Dunnen JT: LOVD v.2.0: the next generation in gene variant databases. Hum Mutat 2011; 32: 557-563.
45. Stenson P, Mort M, Ball E et al: The Human Gene Mutation Database: 2008 update. Genome Med 2009; 1: 13.
46. Muddyman D, Smee C, Griffin H, Kaye J: Implementing a successful data-management framework: the UK10K managed access model. Genome Med 2013; 5: 100.
47. Rodriguez LL, Brooks LD, Greenberg JH, Green ED: The complexities of genomic identifiability. Science 2013; 339: 275-276.
48. MacArthur DG, Balasubramanian S, Frankish A et al: A systematic survey of loss-offunction variants in human protein-coding genes. Science 2012; 335: 823-828.
49. Cooper GM, Shendure J: Needles in stacks of needles: finding disease-causal variants in a wealth of genomic data. Nat Rev Genet 2011; 12: 628-640.
50. Adzhubei IA, Schmidt S, Peshkin L et al: A method and server for predicting damaging missense mutations. Nat Meth 2010; 7: 248-249.
51. Houdayer C, Dehainault C, Mattler C et al: Evaluation of in silico splice tools for decision-making in molecular diagnosis. Human Mutat 2008; 29: 975-982.
52. Harakalova M, van Harssel JJT, Terhal PA et al: Dominant missense mutations in ABCC9 cause Cantu syndrome. Nat Genet 2012; 44: 793-796.
53. Zaghloul NA, Liu Y, Gerdes JM et al: Functional analyses of variants reveal a significant role for dominant negative and common alleles in oligogenic Bardet?ÄìBiedl syndrome. Proc Natl Acad Sci USA 2010;107:10602-10607.
54. Robinson PN, Mundlos S: The human phenotype ontology. Clin Genet 2010; 77: 525-534.
55. Richards CS, Bale S, Bellissimo DB et al: ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med 2008; 10: 294-300.
56. Rigter T, van Aart CJA, Elting MW, Waisfisz Q, Cornel MC, Henneman L: Informed consent for exome sequencing in diagnostics: exploring first experiences and views of professionals and patients. Clin Genet 2014; 85: 417-422.
57. Masys DR, Jarvik GP, Abernethy NF et al: Technical desiderata for the integration of genomic data into Electronic Health Records. J Biomed Inform 2012; 45: 419-422.
58. Jing X, Kay S, Marley T, Hardiker NR, Cimino JJ: Incorporating personalized gene sequence variants, molecular genetics knowledge, and health knowledge into an EHR prototype based on the continuity of care record standard. J Biomed Inform 2012; 45: 82-92.
59. Berg JS, Khoury MJ, Evans JP: Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genet Med 2011; 13: 499-504.
60. Church G, Heeney C, Hawkins N et al: Public access to genome-wide data: five views on balancing research with privacy and protection. PLoS Genet 2009; 5: e1000665.
61. Kaye J, Heeney C, Hawkins N, de Vries J, Boddington P: Data sharing in genomics? re-shaping scientific practice. Nat Rev Genet 2009; 10: 331-335.
62. Murphy J, Scott J, Kaufman D, Geller G, LeRoy L, Hudson K: Public expectations for return of results from large-cohort genetic research. Am J Bioethics 2008; 8: 36-43.
63. Sboner A, Mu XJ, Greenbaum D, Auerbach RK, Gerstein MB: The real cost of sequencing: higher than you think!. Genome Biol 2011; 12: 125.
64. Rios J, Stein E, Shendure J, Hobbs HH, Cohen JC: Identification by whole-genome resequencing of gene defect responsible for severe hypercholesterolemia. Hum Mol Genet 2010; 19: 4313-4318.
65. Wang L, McLeod HL, Weinshilboum RM: Genomics and drug response. N Engl J Med 2011; 364: 1144-1153.
66. Veltman JA, Cuppen E, Vrijenhoek T: Challenges for implementing next-generation sequencing-based genome diagnostics: its also the people, not just the machines. Personalized Med 2013; 10: 473-484.
67. Qureshi N, Modell B, Modell M: Timeline: raising the profile of genetics in primary care. Nat Rev Genet 2004; 5: 783-790.